NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease

2009 ◽  
Vol 25 (4) ◽  
pp. 508-510 ◽  
Author(s):  
Sara Varanese ◽  
Jonathan Howard ◽  
Alessandro Di Rocco
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nmda Antagonist

scholarly journals Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

1991 ◽  
Vol 3 (3) ◽  
pp. 203-213 ◽  
Author(s):  
P. -A. Löschmann ◽  
K. W. Lange ◽  
M. Kunow ◽  
K. -J. Rettig ◽  
P. Jähnig ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nmda Antagonist ◽  
Ampa Antagonist

scholarly journals A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.

1992 ◽  
Vol 55 (7) ◽  
pp. 630-631 ◽  
Author(s):  
J L Montastruc ◽  
O Rascol ◽  
J M Senard ◽  
A Rascol
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Nmda Antagonist

Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease

1997 ◽  
Vol 759 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Anumantha G Kanthasamy ◽  
Arthi Kanthasamy ◽  
Rae R Matsumoto ◽  
Toan Q Vu ◽  
Daniel D Truong
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Experimental Model ◽  
Nmda Antagonist ◽  
Glycine Site ◽  
Neuroprotective Effects

scholarly journals Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Fabrizio Gasparini ◽  
Thérèse Di Paolo ◽  
Baltazar Gomez-Mancilla
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Glutamate Receptors ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptors ◽  
Nmda Antagonist ◽  
Term Treatment ◽  
Metabotropic Receptor ◽  
Long Term Treatment ◽  
Receptor Crosstalk

Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson’s disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskinesia (LID). Although initial preclinical studies with ionotropic glutamate receptor antagonists showed antiparkinsonian and antidyskinetic activity, their clinical use was limited due to psychiatric adverse effects, with the exception of amantadine, a weak N-methyl-d-aspartate (NMDA) antagonist, currently used to reduce dyskinesia in PD patients. Metabotropic receptor (mGlu receptor) modulators were considered to have a more favourable side-effect profile, and several agents have been studied in preclinical models of PD. The most promising results have been seen clinically with selective antagonists of mGlu5 receptor and preclinically with selective positive allosteric modulators of mGlu4 receptor. The growing understanding of glutamate receptor crosstalk also raises the possibility of more precise modulation of glutamatergic transmission, which may lead to the development of more effective agents for PD.

N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan

2004 ◽  
Vol 9 (2) ◽  
pp. 242-243 ◽  
Author(s):  
J. L. Montastruc ◽  
N. Fabre ◽  
O. Rascol ◽  
J. M. Senard ◽  
O. Blin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pilot Study ◽  
Nmda Antagonist

Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease

2002 ◽  
Vol 249 (7) ◽  
pp. 824-828 ◽  
Author(s):  
Norman Putzki ◽  
Matthias Maschke ◽  
Johannes Drepper ◽  
Hans-Chr. Diener ◽  
Dagmar Timmann
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nmda Antagonist ◽  
Postural Responses ◽  
Automatic Postural Responses
Sign in / Sign up

Export Citation Format

Share Document